EGCoviPab-h

EGCoviPab-h is a polyclonal antibody candidate developed by Ace Cells Lab, a UK-based provider of cell lines and reagents. Based on its nomenclature, the agent is likely an equine-derived ("EG") polyclonal antibody ("Pab") directed against SARS-CoV-2 ("Covi"), with the "h" suffix potentially denoting a humanized formulation or a focus on human-related applications. It is positioned within the company's B2B product portfolio alongside cell culture media and other cancer-targeted polyclonal antibodies. While specific clinical development details are limited, equine-derived polyclonal antibodies (typically F(ab')2 fragments) are generally developed as neutralizing agents that bind to the viral spike protein to prevent cellular entry and viral replication. Given its listing as a B2B product, EGCoviPab-h may be intended for use as a research reagent or as a raw material for further diagnostic or therapeutic manufacturing.